$20.08
-1.2%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
ALMS • NASDAQ
| Alumis Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-243.3M | -294.2M | -155M | -111.9M | |
3.5M | 3.2M | 1.3M | 250K | |
-8.6M | 0.0 | 0.0 | 0.0 | |
43.5M | 19.5M | 8.6M | 6M | |
-191M | 1.8M | 3.1M | -86K | |
26.3M | 14.8M | 12.1M | -1.9M | |
-369.5M | -255.1M | -130M | -107.7M | |
INVESTING ACTIVITIES | ||||
-653K | -1.7M | -4.5M | -2.4M | |
-209.2M | -240.1M | -11.3M | -209.1M | |
448M | 128M | 76.3M | 142.7M | |
49.7M | 0.0 | 0.0 | 0.0 | |
(287.9M) | -113.8M | (60.5M) | -68.8M | |
FINANCING ACTIVITIES | ||||
2.1M | 193.3M | 0.0 | 0.0 | |
-17K | (0.0) | (0.0) | (0.0) | |
0.0 | 40.6M | -96K | 1.7M | |
2.1M | 492.4M | 89.7M | 101.6M | |
CASH FLOW SUMMARY | ||||
-79.6M | 123.5M | 20.2M | -74.8M | |
170.6M | 47.1M | 27M | 101.8M | |
91.1M | 170.6M | 47.1M | 27M | |
-370.2M | -256.8M | -134.5M | -110.1M |
ALMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 18, 2026 | June 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 02, 2026 | January 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your ALMS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.